QUALITY INDICATORS OF COLORECTAL CANCER CARE IN CANTON TICINO, SWITZERLAND: DIAGNOSIS, PATHOLOGY AND TREATMENT: THE QC3 STUDY.

Alessandra Spitale1; Laura Ortelli1; Paola Mazzola1; Simona Peverelli2; Luca Mazzucchelli3; Andrea Bordoni1; and the QC3 Colorectal Cancer Working Group3

1 Ticino Cancer Registry, Institute of Pathology, CH-6600 Locarno, Switzerland
2 Institute of Pathology, CH-6600 Locarno, Switzerland
3 the QC3 Colorectal Cancer Working Group: Jessica Barizzi, Floria Bihl, Franco Cavalli, Dimitri Christoforidis, A. Donadini, Alessandra Franzetti-Pellanda, Michele Ghielmini, Luca Giovannella, Juergen Heinkel, Alfred Kuhrmeier, Massimo Maffe, Sebastiano Martinoli, Bernard Miazza, Luca Mazzucchelli, Angelo Pelleoni, Cristiana Quattropani, Raffaele Rosso, Piercarlo Saletti, Maria Carla Valli, Marco Varini, Simone Vannini, Rolf Wyttenbach

Introduction and Objectives
Assessing the quality of cancer care has become increasingly important to providers, regulators and purchasers of care worldwide. Aim of this study is to analyze evidence-based quality indicators (QIs) for colorectal cancer (CRC) care in a population-based setting.

Materials and Methods
All patients diagnosed with CRC in Canton Ticino (southern Switzerland) in the period 2011-2012 are selected. Lymphomas and carcinoids are excluded. QIs are defined using a two-step modified Delphi process involving two multidisciplinary expert panels (a local Working Group and an international Advisory Board) with expertise in CRC care, quality of care and epidemiology (Bianchi V, Spitale A, Ortelli L, et al. BMJ Open 2013;3:e002818. doi:10.1136/bmjopen-2013-002818). QIs are computed for available information, as proportion with the corresponding confidence interval (CI95%).

Results
A total of 474 CRC are diagnosed in Ticino in the two-year considered period. Results of QIs are reported here below:

QI1 = CRC according to the detection method: symptoms 86.9% (CI95%: 83.7%; 90.1%), screening 8.6% (CI95%: 6.0%; 11.3%), accidental finding 4.4% (CI95%: 2.5%; 6.4%);
QI2 = CRC undergoing pre-operative colonoscopy: 90.2% (CI95%: 87.2%; 93.2%);
QI3 = rectal cancers (RC) whose endoscopy/pathology exam report includes the distance ab ano: 83.1% (CI95%: 76.8%; 89.4%);
QI4 = locally advanced RC, whose pathological examination report includes the information of neo-adjuvant radio±chemotherapy (RT±ChT): 86.8% (CI95%: 77.7%; 95.9%);
QI5 = CRC operated in emergency: 8.7% (CI95%: 5.9%; 11.5%);
QI6 = CRC post-operative mortality (within 30 days from the surgery): 3.6% (CI95%: 1.7%; 5.4%);
QI7 = CRC operated on with free margins (R0): 97.2% (CI95%: 95.5%; 98.8%);
QI8 = CRC operated and a number of resected lymph nodes ≥ 12: 86.6% (CI95%: 82.9%; 90.3%);
QI9 = colon cancer (CC) operated and AJCC stage II high-risk or III, undergoing adjuvant chemotherapy (ChT): 47.0% (CI95%: 38.0%; 56.1%);
QI10 = CC operated and AJCC stage II high-risk or III, undergoing adjuvant ChT within 8 weeks from surgical resection: 93.9% (CI95%: 87.2%; 100.0%);
QI11 = locally advanced RC undergoing neo-adjuvant RT±ChT: 66.7% (CI95%: 56.0%; 77.1%);
QI12 = locally advanced RC undergoing neo-adjuvant RT±ChT, operated within 6-8 weeks after the end of neo-adjuvant RT±ChT: 74.0% (CI95%: 61.8%; 86.2%);

Discussion and Conclusions
Although improvements are possible, results are generally positive, encouraging and sometimes more favorable in southern Switzerland in comparison with other international studies on QIs of CRC care. Further national and international population-based data are urgently needed for comparative analysis.

Corresponding Author:
Dr. Alessandra Spitale
Ticino Cancer Registry
Institute of Pathology
Via in Selva, 24. CH-6600 Locarno, Switzerland
Tel: +41-91-8160827. Fax: +41-91-8160829
E-mail: alessandra.spitale@ti.ch